Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials

Advances in Therapy

Volumn 33, Issue 12, 2017, Pages 2188-2199

  Maleki Yazdi, M Reza ^a   Singh, Dave ^b   Anzueto, Antonio ^c   Tombs, Lee ^d   Fahy, William A ^e   Naya, Ian ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d Precise Approach Ltd   (United Kingdom)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Clinically important deterioration; Respiratory; Umeclidinium; Vilanterol

Indexed keywords

TIOTROPIUM BROMIDE; UMECLIDINIUM PLUS VILANTEROL; BENZYL ALCOHOL DERIVATIVE; BRONCHODILATING AGENT; CHLOROBENZENE; QUINUCLIDINE DERIVATIVE; VILANTEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DETERIORATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRY POWDER INHALER; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PNEUMONIA; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; ST. GEORGE RESPIRATORY QUESTIONNAIRE; UPPER RESPIRATORY TRACT INFECTION; AGED; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, INHALATION; AGED; AGED, 80 AND OVER; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; TIOTROPIUM BROMIDE; TREATMENT OUTCOME;

EID: 84992740834     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-016-0430-6     Document Type: Article

References (19)

1. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009;10:59.
2. Troosters T, Sciurba FC, Decramer M, et al. Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial. NPJ Prim Care Respir Med. 2014;24:14003.
3. ® trial. Eur Respir J. 2010;36:65–73.
4. Ferguson GT, Flezar M, Korn S, et al. Efficacy of tiotropium + olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis. Adv Ther. 2015;32:523–36.
5. Dransfield MT, Bailey W, Crater G, et al. Disease severity and symptoms among patients receiving monotherapy for COPD. Prim Care Respir J. 2010;20:46.
6. Jones PW. St. George’s respiratory questionnaire: MCID. COPD. 2005;2:75–9.
7. Westwood M, Bourbeau J, Jones PW, et al. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011;12:40.
8. Wilke S, Spruit MA, Wouters EF, et al. Determinants of 1-year changes in disease-specific health status in patients with advanced chronic obstructive pulmonary disease: a 1-year observational study. Int J Nurs Pract. 2015;21:239–48.
9. Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2:111–24.
10. GOLD. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease http://www.goldcopd.com/. Accessed Aug 2015.
11. Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108:1752–60.
12. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2:472–86.
13. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–46.
14. Renard D, Looby M, Kramer B, et al. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir Res. 2011;12:54.
15. Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy B, Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11(1):1413–24.
16. Naya I, Tombs L, Jones P. Short-term clinically important deterioration predicts long-term clinical outcome in copd patients: a post hoc analysis of the torch trial. Thorax. 2015;70:A1–254.
17. Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:95–9.
18. Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374:1171–8.
19. Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71:15–25.